Clinical Trial Update: Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating TNG348 alone and in combination with a PARP inhibitor for BRCA1/2-mutant or HRD-positive solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer

Drugs mentioned

• PARP inhibitor (unspecified)
• TNG348

Snippet

Sponsor: Tango Therapeutics, Inc. | Conditions: Breast Cancer, Ovarian Cancer | Phase 1, Phase 2 | Status: TERMINATED